ArticleTranslational gastroenterology and hepatology2025
Early diagnosis of liver graft steatosis and fibrosis: are non-invasive tests the answer?
Article in Translational gastroenterology and hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Graft steatosis and fibrosis detection is a challenge to avoid graft loss. The role of liver biopsy (LB) after liver transplantation (LT) is changing with the emergence of non-invasive tests. Our aim is to evaluate the accuracy of transient elastography (TE) in predicting steatosis and fibrosis post-LT. Methods: This prospective study was performed on 158 LT patients. Controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) were carried out prior to LB. We built receiver operating characteristic (ROC) curves to evaluate the predictive performance of TE. Results: Using CAP, the area under the curve (AUC) were 0.872 [95% confidence interval (CI): 0.791-0.953, P=0.01] and 0.708 (95% CI: 0.614-0.801, P<0.001) for the diagnosis of steatosis ≥ S2 and ≥ S1, respectively. Using LSM, the AUC were 0.588 (95% CI: 0.486-0.691, P=0.10) and 0.651 (95% CI: 0.480-0.822, P=0.10) for the diagnosis of fibrosis ≥ F2 and F3-F4, respectively. Cut-offs for CAP were 246.5 dB/m for S1 and 275.5 dB/m for S2. Cut-offs for LSM were 7.65 kPa for ≥ F2 and 9.25 kPa for ≥ F3. Conclusions: TE may be useful for screening advanced fibrosis and, interestingly, steatosis after LT. TE might gain relevance to track graft metabolic dysfunction and to propose lifestyle interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.